Kidney Tests for Diabetes Monitoring

Annual kidney tests for diabetes monitoring are among the most clinically impactful screening tests in all of diabetes care — not because diabetic kidney disease is a rare or niche complication, but because it is extremely common (affecting approximately 40% of adults with Type 2 diabetes to some degree), because it is largely silent until it has progressed to advanced stages, and because early detection enables treatments that can substantially slow or even stabilize its progression. The two primary kidney tests for diabetes monitoring — the urine albumin-to-creatinine ratio (uACR) and the estimated glomerular filtration rate (eGFR) — are simple, inexpensive, and available through routine laboratory testing, yet they are missed in a substantial proportion of annual diabetes monitoring cycles. Understanding what each test measures, what the results mean, and what actions they trigger is essential knowledge for any adult with Type 2 diabetes who wants to protect their kidney function over the decades-long course of the disease.

The Urine Albumin Test: Detecting Early Kidney Damage

The urine albumin-to-creatinine ratio (uACR) is the primary screening test for early diabetic nephropathy. Understanding what it measures and how to interpret the result helps adults with diabetes appreciate the significance of this annual test:

• What the test measures: Albumin is a blood protein that is normally prevented from entering the urine by the kidney’s filtration barrier (the glomerular basement membrane). When elevated blood glucose damages the small blood vessels of the glomerulus over time, this filtration barrier becomes “leaky” — allowing albumin to pass into the urine in amounts that can be detected by laboratory testing. The uACR measures the ratio of albumin to creatinine in a single urine sample (most commonly a spot morning urine sample), which normalizes the albumin measurement for urine concentration and provides a result that reflects 24-hour albumin excretion without requiring a 24-hour urine collection. The test is straightforward for patients — a single urine sample collected at the laboratory or at home and brought to the lab is sufficient.
• Interpreting uACR results: A normal uACR is below 30 mg/g. Results of 30–300 mg/g indicate moderately increased albuminuria (formerly called microalbuminuria) — the earliest detectable stage of diabetic nephropathy. Results above 300 mg/g indicate severely increased albuminuria (formerly called macroalbuminuria or overt proteinuria) — a more advanced stage of kidney damage. A single elevated uACR result should be confirmed with repeat testing on 2 occasions over 3 months, because transient elevations can occur with urinary tract infections, intense exercise, fever, or very high blood pressure — conditions that cause temporary increases in urinary albumin that are not representative of chronic kidney damage.
• What an elevated uACR triggers: A confirmed uACR above 30 mg/g should trigger: (1) initiation or intensification of ACE inhibitor or ARB therapy (which reduces glomerular filtration pressure and slows albumin excretion and kidney disease progression); (2) consideration of adding an SGLT2 inhibitor (which has demonstrated renal protective effects in multiple large randomized trials including CREDENCE and DAPA-CKD); (3) more intensive blood pressure management targeting below 130/80 mmHg; (4) more frequent kidney function monitoring (uACR and eGFR every 3–6 months rather than annually); and (5) nephrology referral if the uACR is significantly elevated, rising rapidly, or associated with declining eGFR. The urine albumin test in the context of the full kidney monitoring framework is covered in our urine albumin test and diabetes guide.

The eGFR Test: Measuring Kidney Filtration Function

The estimated glomerular filtration rate (eGFR) is the second primary kidney test for diabetes monitoring. Unlike the uACR, which detects early kidney damage before function is lost, the eGFR measures how much filtration function remains — making it the primary tool for staging kidney disease and for determining medication adjustments as function declines:

• How eGFR is calculated: The eGFR is not a direct measurement but a calculation derived from serum creatinine (a waste product of muscle metabolism that the kidneys filter and excrete), patient age, and sex. The most commonly used equation (CKD-EPI) produces an eGFR in units of mL/min/1.73m² — representing the estimated volume of blood that the kidneys filter per minute, normalized to a standard body surface area. A higher eGFR means better kidney function; a lower eGFR means reduced filtration capacity. Most healthy adults have eGFRs of 90–120 mL/min/1.73m²; values decline with age even in the absence of kidney disease (by approximately 0.7–1 mL/min/1.73m² per year after age 40), which is factored into the CKD-EPI equation.
• CKD staging by eGFR: Chronic kidney disease is classified into five stages based on eGFR: G1 (eGFR ≥90 — normal or high, but with evidence of kidney damage such as elevated uACR); G2 (eGFR 60–89 — mildly reduced); G3a (eGFR 45–59 — mildly to moderately reduced); G3b (eGFR 30–44 — moderately to severely reduced); G4 (eGFR 15–29 — severely reduced); G5 (eGFR <15 or on dialysis — kidney failure). For adults with diabetes and CKD, both the eGFR stage and the uACR category are used together to classify kidney disease severity and guide management — a patient with G3a CKD and severely increased albuminuria (ACR above 300) is at higher risk of progression than a G3a patient with normal albumin excretion.
• Medication adjustments triggered by declining eGFR: Several diabetes medications require dose adjustment or discontinuation as eGFR declines. Metformin: reduce dose at eGFR 30–45 mL/min/1.73m², contraindicated below 30. Glyburide: use with extreme caution below 60, avoid below 30 due to active metabolite accumulation. SGLT2 inhibitors: glucose-lowering efficacy decreases below eGFR 45, though renal protection may persist to lower eGFR levels (empagliflozin approved to eGFR 20 for its heart failure indication). Insulin: doses may need reduction as kidney function declines because the kidney contributes to insulin clearance. Knowing the current eGFR is not just relevant for kidney management — it is essential for safe prescribing of multiple medications that are routinely used in adults with Type 2 diabetes. The eGFR in detail is covered in our eGFR and kidney function in diabetes guide. The SGLT2 inhibitors that provide kidney protection at specific eGFR thresholds are covered in our SGLT2 inhibitors explained guide. The full medication safety implications of kidney disease for diabetes medications are in our diabetes medication safety guide. The annual monitoring schedule that places kidney tests alongside all other required annual monitoring is in our annual diabetes care checklist. The NIDDK’s diabetic kidney disease resources, the National Kidney Foundation’s diabetes and CKD guidance, and the KDIGO diabetes and CKD guidelines provide authoritative clinical information on kidney monitoring and management in adults with diabetes.

Preventing Diabetic Kidney Disease Progression: What Works

Once the annual kidney tests for diabetes monitoring have identified diabetic nephropathy — whether early (elevated uACR) or established (declining eGFR) — the interventions that can slow or stabilize progression are well-established and effective when started early:

• Blood glucose control: The most fundamental intervention for preventing the initial development and early progression of diabetic nephropathy is long-term blood glucose control. The UKPDS and DCCT/EDIC trials established that HbA1c reduction significantly reduces the risk of microalbuminuria developing in adults without existing kidney damage, and slows progression in those with early nephropathy. The effect is most pronounced in early disease — once kidney function has declined significantly (eGFR below 30–45 mL/min/1.73m²), the independent impact of blood glucose control on kidney disease trajectory becomes smaller relative to the effects of blood pressure and RAAS blockade, but remains relevant for overall diabetes management. The A1C testing that monitors blood glucose control over time is covered in our A1C testing schedule guide.
• Blood pressure control with ACE inhibitors or ARBs: ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, irbesartan) reduce intraglomerular pressure by dilating the efferent arteriole of the glomerulus, reducing the mechanical stress on the glomerular filtration barrier and slowing albumin excretion and kidney disease progression. These medications provide kidney protection beyond their blood pressure-lowering effect — clinical trials have shown that RAAS blockade reduces the rate of progression from microalbuminuria to macroalbuminuria and from macroalbuminuria to eGFR decline in adults with diabetic nephropathy, independent of the blood pressure reduction. Current guidelines recommend ACE inhibitors or ARBs as first-line antihypertensive therapy for adults with diabetes and elevated uACR (above 30 mg/g) or reduced eGFR, with blood pressure targets below 130/80 mmHg. The blood pressure monitoring that tracks whether the target is being achieved is in our blood pressure monitoring in diabetes guide.
• SGLT2 inhibitors — the most significant advance in diabetic kidney disease treatment in decades: The CREDENCE trial (2019) demonstrated that canagliflozin significantly reduced the composite endpoint of kidney failure, dialysis, transplant, doubling of serum creatinine, and cardiovascular and kidney death in adults with Type 2 diabetes and diabetic kidney disease — a landmark result that established SGLT2 inhibitors as a disease-modifying treatment for diabetic nephropathy alongside ACE inhibitors and ARBs. The DAPA-CKD trial (2020) showed similar renal protective effects with dapagliflozin in adults with CKD with and without diabetes. The EMPA-KIDNEY trial (2022) confirmed empagliflozin’s renal protective effect across a broad CKD population. The combined evidence from these trials has made SGLT2 inhibitor therapy a recommended first-line intervention for adults with Type 2 diabetes and CKD with eGFR above 20 mL/min/1.73m² in current ADA and KDIGO guidelines — an important advance because these drugs now offer protection beyond what ACE inhibitors alone can provide. The comprehensive SGLT2 inhibitor guide is in our SGLT2 inhibitors explained article.
• GLP-1 receptor agonists for cardiovascular and renal risk reduction: Cardiovascular outcome trials for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) consistently show secondary renal benefits — reductions in new or worsening nephropathy, reduction in macroalbuminuria, and in some analyses attenuation of eGFR decline — in addition to the primary cardiovascular endpoints these trials were powered to assess. The FLOW trial (semaglutide for CKD) confirmed a direct kidney protective benefit of semaglutide in adults with Type 2 diabetes and CKD. For adults with both cardiovascular risk and CKD, the combination of an SGLT2 inhibitor and a GLP-1 receptor agonist is increasingly considered to provide complementary, additive protection across both cardiovascular and renal end points.
• Dietary protein moderation: Some evidence supports modest dietary protein restriction (below 0.8 g/kg/day rather than higher protein diets) in adults with established CKD, as reducing dietary protein may reduce glomerular filtration pressure and slow nephropathy progression. This dietary guidance is most relevant in advanced CKD (eGFR below 30 mL/min/1.73m²) and should be developed with the prescribing clinician and a renal dietitian — unsupervised extreme protein restriction can cause malnutrition and should be avoided.
• Avoidance of nephrotoxic agents: Adults with CKD should avoid or use with extreme caution NSAIDs (ibuprofen, naproxen), certain antibiotics (aminoglycosides), and nephrotoxic contrast dye used in imaging procedures — all of which can cause acute kidney injury that is superimposed on chronic kidney disease and accelerates permanent function loss. Metformin should be held before contrast procedures and resumed only after kidney function is confirmed to be stable. The medication safety practices that cover these situations are in our diabetes medication safety guide. The complete annual monitoring framework that ensures kidney test results trigger appropriate management changes is in our annual diabetes care checklist. The overall diabetes checkup context that places kidney tests within the full monitoring schedule is in our diabetes checkups: what to expect guide. The NIDDK’s diabetic kidney disease resources, the National Kidney Foundation, and the KDIGO diabetes and CKD guidelines provide the authoritative clinical basis for kidney monitoring and management in adults with diabetes.

When to See a Nephrologist (Kidney Specialist)

Referral to a nephrologist is an important component of diabetes kidney care for adults with established or rapidly declining kidney disease. The specific criteria for nephrology referral from kidney test results include:

• eGFR below 30 mL/min/1.73m² (CKD Stage G4–G5): At this level of kidney function, management complexity increases substantially — multiple medications require adjustment or discontinuation, anemia of CKD may require erythropoiesis-stimulating agents, metabolic acidosis and mineral bone disease need monitoring and treatment, and preparation for renal replacement therapy (dialysis or kidney transplant evaluation) becomes relevant. Nephrology co-management with primary care is standard of care at this stage.
• Rapid eGFR decline: A drop in eGFR of more than 5 mL/min/1.73m² in one year or more than 10 mL/min/1.73m² in five years — even within ranges where kidney function is not yet severely reduced — is concerning for accelerated kidney disease progression and warrants nephrology evaluation to identify and address modifiable causes.
• Uncertainty about the cause of kidney disease: In most adults with longstanding diabetes, hypertension, and gradually declining kidney function with proteinuria, the diagnosis of diabetic nephropathy can be made clinically without kidney biopsy. However, when the presentation is atypical — kidney disease developing rapidly, without proteinuria, associated with hematuria (blood in urine), or in a patient with very short diabetes duration — other causes of kidney disease (IgA nephropathy, membranous nephropathy, hypertensive nephrosclerosis, other glomerulopathies) should be excluded, and nephrology input guides whether kidney biopsy is indicated. The complete context of all diabetes-related monitoring — including how kidney test results connect to medication management and cardiovascular risk — is throughout our annual diabetes care checklist and diabetes checkups guide.

Understanding Your Kidney Test Results: What the Numbers Mean

Many adults with diabetes who receive their kidney test results in a lab report or patient portal don’t know how to interpret the numbers without a clinical explanation. Here is a plain-language guide to reading the two key kidney monitoring results:

• Reading your eGFR result: Your eGFR lab report will show a number in mL/min/1.73m² alongside a flag for “low” or “normal.” Many labs flag any eGFR below 60 as abnormal. If your eGFR is: above 90 — normal kidney filtration function (unless there is accompanying uACR elevation or imaging abnormality indicating kidney damage); 60–89 — mildly reduced; 45–59 — mildly to moderately reduced (many diabetes medications need dose review at this level); 30–44 — moderately to severely reduced (significant medication adjustments needed, more frequent monitoring); 15–29 — severely reduced (preparation for kidney replacement therapy should be discussed with a nephrologist); below 15 — kidney failure, requiring dialysis or transplant planning. Note that a single eGFR reading is less informative than a trend over 2–3 years — one stable reading of 58 in an adult whose previous readings were also 58–62 is far less concerning than a drop from 75 to 58 over two years. Always ask for the trend, not just the current number.
• Reading your uACR result: Your urine albumin result may be reported as uACR (urine albumin-to-creatinine ratio) in mg/g, or it may be reported as “urine microalbumin” in mcg/mg (which is equivalent). Below 30 mg/g is normal. Between 30 and 300 mg/g indicates early kidney damage — meaningful even though your kidneys are still filtering normally by eGFR measurement. Above 300 mg/g indicates more significant kidney damage and warrants more intensive treatment. If your result is elevated, ask for it to be repeated on at least one more occasion before treatment decisions are made, because temporary elevations (UTI, recent vigorous exercise, fever) are common and should not drive long-term treatment changes.
• The combined interpretation: The current KDIGO (Kidney Disease: Improving Global Outcomes) CKD classification system uses both eGFR and uACR together to assess CKD severity and risk of progression. A person with eGFR 55 and uACR below 30 is in a much lower-risk category than a person with eGFR 55 and uACR above 300 — even though their filtration function is identical by eGFR. The combination of the two tests together tells a more complete story than either test alone: eGFR tells you how much kidney function remains; uACR tells you how actively the kidney is being damaged. Stable eGFR with low uACR suggests stabilization; declining eGFR with rising uACR suggests active, progressive disease requiring intensified intervention. Tracking both numbers at every monitoring visit — and understanding which direction each is moving — is the most informative use of the annual kidney test data. The complete diabetes monitoring context that ensures kidney test results are acted on appropriately is in our annual diabetes care checklist. The individual test guides — covering urine albumin in detail and eGFR in detail — are in our urine albumin test and diabetes and eGFR and kidney function in diabetes articles. The cholesterol monitoring that accompanies kidney monitoring in the annual diabetes checkup is in our cholesterol monitoring in diabetes guide. The NIDDK’s diabetic kidney disease resources, the National Kidney Foundation, and the KDIGO guidelines provide authoritative clinical guidance on kidney monitoring interpretation and management in adults with diabetes.

The central practical message about kidney tests for diabetes monitoring is that they must be completed annually — not assumed to be normal, not skipped because the person feels fine, and not deferred because no symptoms are present. Diabetic nephropathy is completely silent in its early stages: the elevated urine albumin that signals early kidney damage causes no symptoms that the person can feel, and the declining eGFR that marks progressive kidney disease is typically unnoticed until it reaches stages that are difficult to reverse. The annual uACR and eGFR tests are the only way to know what is actually happening in the kidneys — and the interventions available at early stages (blood glucose control, ACE inhibitors, SGLT2 inhibitors, blood pressure management) can genuinely change the long-term trajectory of kidney disease in ways that are no longer possible once the disease has reached advanced stages. Every year that kidney damage is detected and treated earlier represents years of preserved kidney function later. For adults with diabetes who are uncertain whether their kidney tests are current, asking at the next primary care visit — “When were my last urine albumin and kidney function tests, and are they due again?” — is one of the most impactful questions they can ask for their long-term health.

Sources: American Diabetes Association — Standards of Medical Care in Diabetes, diabetic kidney disease monitoring and management recommendations; NIDDK — diabetic kidney disease resources; National Kidney Foundation — diabetes and CKD guidance; KDIGO (Kidney Disease: Improving Global Outcomes) — diabetes and CKD 2022 guidelines; CKD-EPI eGFR equation and its application; urine albumin-to-creatinine ratio (uACR) interpretation: normal (<30 mg/g), moderately increased (30–300 mg/g), severely increased (>300 mg/g); CKD staging by eGFR: G1-G5 classification system; CREDENCE trial (canagliflozin renal outcomes) and DAPA-CKD trial (dapagliflozin CKD outcomes); ACE inhibitor and ARB renal protection evidence in diabetic nephropathy; metformin eGFR-based dosing recommendations; diabetic kidney disease prevalence data from USRDS and NHANES; transition from early to advanced CKD timeline and intervention window data.